Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 8 (RPL23AP8) is a processed pseudogene related to the ribosomal protein L23a gene. Pseudogenes are genomic DNA sequences similar to normal genes but generally nonfunctional; they usually do not encode functional proteins due to mutations or lack of regulatory elements. RPL23AP8 belongs to a family of over ninety processed pseudogenes derived from the protein-coding RPL23A gene, which encodes a structural component of the 60S ribosomal subunit[5][6]. There is no evidence supporting a direct functional or pathological role of RPL23AP8 itself, nor is it considered a therapeutic target. The biological roles of ribosomal protein pseudogenes overall are largely unknown, though some may participate in the regulation of gene expression, such as acting as competitive endogenous RNAs; however, no such function has been established for RPL23AP8 specifically[3][6]. There is no evidence linking RPL23AP8 to any diseases, drug interactions, or clinical biomarker use. For other pseudogenes of RPL23A (e.g., RPL23AP53), some research suggests association with altered expression in cancer, but these findings are gene-specific and do not generalize to RPL23AP8[3].\n\nThe true protein-coding gene, RPL23A, encodes a ribosomal subunit protein involved in protein synthesis and has been studied as an autoimmune target[5]. RPL23AP8 is distinctly annotated as a pseudogene in gene databases; there is no evidence or annotation suggesting it produces a functional protein[6]. Catalogs and biological reagent providers list RPL23AP8 among other ribosomal protein pseudogenes, all being classified as noncoding[1][2][4]. Some studies report altered expression of certain RPL23A pseudogenes (for example, RPL23AP53) in cancer but do not comment on RPL23AP8[3].\n\nThis is not a therapeutic target—it is a pseudogene, not a functional protein, receptor, or enzyme, and currently has no direct clinical, functional, or pharmacological relevance[5][6][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 8 (RPL23AP8).